Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Ferreira, João P; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans-Peter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; +32 more... Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L; Gonzalez-Juanatey, Jose R; Merkely, Bela; Nicholls, Stephen J; Perrone, Sergio V; Piña, Ileana L; Ponikowski, Piotr; Senni, Michele; Sim, David; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragos; Zhang, Jian; Carson, Peter; Lam, Carolyn Su Ping; Marx, Nikolaus; Zeller, Cordula; Sattar, Naveed; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet M; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Investigators; (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 385 (16). pp. 1451-1461. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa2107038

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1056/NEJMoa2107038

Abstract

Item Type Article
Faculty and Department Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Research Centre Clinical Trials Unit
PubMed ID 34449189
Elements ID 165862

Share

Download

Filename: nejmoa2107038.pdf

Licence: Copyright the publishers

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar